Docosahexaenoic acid enhances oxaliplatin-induced autophagic cell death via the ER stress/sesn2 pathway in colorectal cancer

Soyeon Jeong, Dae Yeong Kim, Sang Hee Kang, Hye Kyeong Yun, Jung Lim Kim, Bo Ram Kim, Seong Hye Park, Yoo Jin Na, Min Jee Jo, Yoon A. Jeong, Bu Gyeom Kim, Dae Hee Lee, Sang Cheul Oh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Oxaliplatin is an anticancer drug administered to colorectal cancer (CRC) patients in combination with 5-fluorouracil and antibodies (bevacizumab and cetuximab), thereby significantly improving the survival rate of CRC. However, due to various side effects associated with the above treatment strategy, the need for combinatorial therapeutic strategies has emerged. Based on the demand for new combinatorial therapies and the known antitumor effects of the omega-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA), we investigated the Oxaliplatin and DHA combination for its effect. Our results indicated that DHA further enhanced Oxaliplatin-induced cell viability and autophagic cell death, in vitro and in vivo. Oxaliplatin and DHA also increased the expression of Sestrin 2 (SESN2) and endoplasmic reticulum (ER) stress related C/EBP homologous protein (CHOP). Additionally, treatment with Oxaliplatin and DHA enhanced the binding of CHOP to the promotor region of SESN2, increasing SESN2 expression. These results suggested that DHA enhanced Oxaliplatin-induced reduction in cell viability and increase in autophagy via activating SESN2 and increasing ER stress. Thus, SESN2 may be an effective preclinical target for CRC treatment.

Original languageEnglish
Article number982
JournalCancers
Volume11
Issue number7
DOIs
Publication statusPublished - 2019 Jul 1

Fingerprint

oxaliplatin
Endoplasmic Reticulum Stress
Docosahexaenoic Acids
Autophagy
Colorectal Neoplasms
Transcription Factor CHOP
Cell Survival
Therapeutics
Omega-3 Fatty Acids
Unsaturated Fatty Acids
Genetic Promoter Regions
Fluorouracil
Survival Rate

Keywords

  • Autophagic cell death
  • Colon cancer
  • Docosahexaenoic acid
  • Oxaliplatin
  • Sestrin 2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Docosahexaenoic acid enhances oxaliplatin-induced autophagic cell death via the ER stress/sesn2 pathway in colorectal cancer. / Jeong, Soyeon; Kim, Dae Yeong; Kang, Sang Hee; Yun, Hye Kyeong; Kim, Jung Lim; Kim, Bo Ram; Park, Seong Hye; Na, Yoo Jin; Jo, Min Jee; Jeong, Yoon A.; Kim, Bu Gyeom; Lee, Dae Hee; Oh, Sang Cheul.

In: Cancers, Vol. 11, No. 7, 982, 01.07.2019.

Research output: Contribution to journalArticle

Jeong, S, Kim, DY, Kang, SH, Yun, HK, Kim, JL, Kim, BR, Park, SH, Na, YJ, Jo, MJ, Jeong, YA, Kim, BG, Lee, DH & Oh, SC 2019, 'Docosahexaenoic acid enhances oxaliplatin-induced autophagic cell death via the ER stress/sesn2 pathway in colorectal cancer', Cancers, vol. 11, no. 7, 982. https://doi.org/10.3390/cancers11070982
Jeong, Soyeon ; Kim, Dae Yeong ; Kang, Sang Hee ; Yun, Hye Kyeong ; Kim, Jung Lim ; Kim, Bo Ram ; Park, Seong Hye ; Na, Yoo Jin ; Jo, Min Jee ; Jeong, Yoon A. ; Kim, Bu Gyeom ; Lee, Dae Hee ; Oh, Sang Cheul. / Docosahexaenoic acid enhances oxaliplatin-induced autophagic cell death via the ER stress/sesn2 pathway in colorectal cancer. In: Cancers. 2019 ; Vol. 11, No. 7.
@article{08b21ddc0c214c1080143fec49f53b6e,
title = "Docosahexaenoic acid enhances oxaliplatin-induced autophagic cell death via the ER stress/sesn2 pathway in colorectal cancer",
abstract = "Oxaliplatin is an anticancer drug administered to colorectal cancer (CRC) patients in combination with 5-fluorouracil and antibodies (bevacizumab and cetuximab), thereby significantly improving the survival rate of CRC. However, due to various side effects associated with the above treatment strategy, the need for combinatorial therapeutic strategies has emerged. Based on the demand for new combinatorial therapies and the known antitumor effects of the omega-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA), we investigated the Oxaliplatin and DHA combination for its effect. Our results indicated that DHA further enhanced Oxaliplatin-induced cell viability and autophagic cell death, in vitro and in vivo. Oxaliplatin and DHA also increased the expression of Sestrin 2 (SESN2) and endoplasmic reticulum (ER) stress related C/EBP homologous protein (CHOP). Additionally, treatment with Oxaliplatin and DHA enhanced the binding of CHOP to the promotor region of SESN2, increasing SESN2 expression. These results suggested that DHA enhanced Oxaliplatin-induced reduction in cell viability and increase in autophagy via activating SESN2 and increasing ER stress. Thus, SESN2 may be an effective preclinical target for CRC treatment.",
keywords = "Autophagic cell death, Colon cancer, Docosahexaenoic acid, Oxaliplatin, Sestrin 2",
author = "Soyeon Jeong and Kim, {Dae Yeong} and Kang, {Sang Hee} and Yun, {Hye Kyeong} and Kim, {Jung Lim} and Kim, {Bo Ram} and Park, {Seong Hye} and Na, {Yoo Jin} and Jo, {Min Jee} and Jeong, {Yoon A.} and Kim, {Bu Gyeom} and Lee, {Dae Hee} and Oh, {Sang Cheul}",
year = "2019",
month = "7",
day = "1",
doi = "10.3390/cancers11070982",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

TY - JOUR

T1 - Docosahexaenoic acid enhances oxaliplatin-induced autophagic cell death via the ER stress/sesn2 pathway in colorectal cancer

AU - Jeong, Soyeon

AU - Kim, Dae Yeong

AU - Kang, Sang Hee

AU - Yun, Hye Kyeong

AU - Kim, Jung Lim

AU - Kim, Bo Ram

AU - Park, Seong Hye

AU - Na, Yoo Jin

AU - Jo, Min Jee

AU - Jeong, Yoon A.

AU - Kim, Bu Gyeom

AU - Lee, Dae Hee

AU - Oh, Sang Cheul

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Oxaliplatin is an anticancer drug administered to colorectal cancer (CRC) patients in combination with 5-fluorouracil and antibodies (bevacizumab and cetuximab), thereby significantly improving the survival rate of CRC. However, due to various side effects associated with the above treatment strategy, the need for combinatorial therapeutic strategies has emerged. Based on the demand for new combinatorial therapies and the known antitumor effects of the omega-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA), we investigated the Oxaliplatin and DHA combination for its effect. Our results indicated that DHA further enhanced Oxaliplatin-induced cell viability and autophagic cell death, in vitro and in vivo. Oxaliplatin and DHA also increased the expression of Sestrin 2 (SESN2) and endoplasmic reticulum (ER) stress related C/EBP homologous protein (CHOP). Additionally, treatment with Oxaliplatin and DHA enhanced the binding of CHOP to the promotor region of SESN2, increasing SESN2 expression. These results suggested that DHA enhanced Oxaliplatin-induced reduction in cell viability and increase in autophagy via activating SESN2 and increasing ER stress. Thus, SESN2 may be an effective preclinical target for CRC treatment.

AB - Oxaliplatin is an anticancer drug administered to colorectal cancer (CRC) patients in combination with 5-fluorouracil and antibodies (bevacizumab and cetuximab), thereby significantly improving the survival rate of CRC. However, due to various side effects associated with the above treatment strategy, the need for combinatorial therapeutic strategies has emerged. Based on the demand for new combinatorial therapies and the known antitumor effects of the omega-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA), we investigated the Oxaliplatin and DHA combination for its effect. Our results indicated that DHA further enhanced Oxaliplatin-induced cell viability and autophagic cell death, in vitro and in vivo. Oxaliplatin and DHA also increased the expression of Sestrin 2 (SESN2) and endoplasmic reticulum (ER) stress related C/EBP homologous protein (CHOP). Additionally, treatment with Oxaliplatin and DHA enhanced the binding of CHOP to the promotor region of SESN2, increasing SESN2 expression. These results suggested that DHA enhanced Oxaliplatin-induced reduction in cell viability and increase in autophagy via activating SESN2 and increasing ER stress. Thus, SESN2 may be an effective preclinical target for CRC treatment.

KW - Autophagic cell death

KW - Colon cancer

KW - Docosahexaenoic acid

KW - Oxaliplatin

KW - Sestrin 2

UR - http://www.scopus.com/inward/record.url?scp=85071395901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071395901&partnerID=8YFLogxK

U2 - 10.3390/cancers11070982

DO - 10.3390/cancers11070982

M3 - Article

AN - SCOPUS:85071395901

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 7

M1 - 982

ER -